8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Mar 30, 2026·SEC
Sight Sciences, Inc.(SGHT)Earnings, Financials & Key Ratios
SGHT•NASDAQ
Price updated Jun 19, 2026
AboutSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.Show more
- Revenue$77M-3.1%
- EBITDA-$37M+26.5%
- Net Income-$38M+25.4%
- EPS (Diluted)-0.74+28.2%
- Gross Margin86.17%+0.8%
- EBITDA Margin-47.32%+24.1%
- Operating Margin-47.95%+24.2%
- Net Margin-49.67%+23.0%
- ROE-50.74%-2.3%
SGHT Key Insights
Sight Sciences, Inc. (SGHT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 22.9%
✗Weaknesses
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SGHT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SGHT Price & Volume
Sight Sciences, Inc. (SGHT) stock price & volume — 10-year historical chart
Loading chart...
SGHT Growth Metrics
Sight Sciences, Inc. (SGHT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years22.86%
3 Years2.74%
TTM1.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM24.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.71%
Return on Capital
10 Years-85.68%
5 Years-33.64%
3 Years-33.55%
Last Year-32.03%
SGHT Recent Earnings
Sight Sciences, Inc. (SGHT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.16+15.8%
$0.19
Rev
$20M+6.7%
$18M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.08+46.7%
$0.15
Rev
$20M+0.2%
$20M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.16+38.5%
$0.26
Rev
$20M-2.2%
$20M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.23+8.0%
$0.25
Rev
$20M+10.3%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.16vs $0.19+15.8% | $20Mvs $18M+6.7% |
| Q2 2026 | Mar 4, 2026 | $0.08vs $0.15+46.7% | $20Mvs $20M+0.2% |
| Q4 2025 | Nov 6, 2025 | $0.16vs $0.26+38.5% | $20Mvs $20M-2.2% |
| Q3 2025 | Aug 7, 2025 | $0.23vs $0.25+8.0% | $20Mvs $18M+10.3% |
Based on last 12 quarters of dataView full earnings history →
SGHT Peer Comparison
Sight Sciences, Inc. (SGHT) competitors in Vision, dental, and ENT devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GKOS | 7.65B | 130.68 | -39.84 | 32.33% | -34.34% | -26.46% | 0.21 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 MASI | 9.42B | 179.95 | -64.27 | -27.1% | 4.9% | 9.08% | 0.78 | |
 TNDM | 1.05B | 15.30 | -5.03 | 7.93% | -9.2% | -68.29% | 2.86 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 |
Compare SGHT vs Peers
Sight Sciences, Inc. (SGHT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SGHT Income Statement
Sight Sciences, Inc. (SGHT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.53M | 23.35M | 27.64M | 48.96M | 71.33M | 81.06M | 79.87M | 77.36M | 79.55M |
Revenue Growth % | - | 210.07% | 18.38% | 77.12% | 45.7% | 13.63% | -1.47% | -3.13% | 1.85% |
Cost of Goods Sold | 2.34M | 6.54M | 9.21M | 8.61M | 12.36M | 11.88M | 11.58M | 10.7M | 11M |
COGS % of Revenue | 31.05% | 28.03% | 33.32% | 17.59% | 17.33% | 14.66% | 14.5% | 13.83% | - |
Gross Profit | 5.19M▲ 0% | 16.8M▲ 223.7% | 18.43M▲ 9.7% | 40.35M▲ 118.9% | 58.97M▲ 46.2% | 69.17M▲ 17.3% | 68.28M▼ 1.3% | 66.67M▼ 2.4% | 68.55M▲ 0% |
Gross Margin % | 68.95% | 71.97% | 66.68% | 82.41% | 82.67% | 85.34% | 85.5% | 86.17% | 86.17% |
Gross Profit Growth % | - | 223.65% | 9.68% | 118.9% | 46.16% | 17.31% | -1.29% | -2.37% | - |
Operating Expenses | 19.49M | 40.84M | 50.62M | 91.82M | 142.92M | 126.45M | 118.82M | 103.77M | 104.2M |
OpEx % of Revenue | 258.82% | 174.93% | 183.14% | 187.56% | 200.37% | 156% | 148.77% | 134.13% | - |
Selling, General & Admin | 14.06M | 32.72M | 41.74M | 76.19M | 120.06M | 108.89M | 100.83M | 89.16M | 91.48M |
SG&A % of Revenue | 186.76% | 140.14% | 151.03% | 155.63% | 168.32% | 134.34% | 126.24% | 115.25% | - |
Research & Development | 5.43M | 8.12M | 8.87M | 15.63M | 22.86M | 17.56M | 17.99M | 14.61M | 12.72M |
R&D % of Revenue | 72.06% | 34.8% | 32.11% | 31.93% | 32.05% | 21.66% | 22.53% | 18.88% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -14.3M▲ 0% | -24.04M▼ 68.1% | -32.19M▼ 33.9% | -51.48M▼ 59.9% | -83.95M▼ 63.1% | -57.27M▲ 31.8% | -50.53M▲ 11.8% | -37.1M▲ 26.6% | -35.65M▲ 0% |
Operating Margin % | -189.87% | -102.96% | -116.45% | -105.15% | -117.7% | -70.66% | -63.27% | -47.95% | -44.82% |
Operating Income Growth % | - | -68.14% | -33.9% | -59.93% | -63.09% | 31.78% | 11.77% | 26.58% | - |
EBITDA | -14.23M | -23.61M | -31.63M | -50.28M | -82.7M | -56.66M | -49.82M | -36.61M | -35.32M |
EBITDA Margin % | -189.03% | -101.11% | -114.45% | -102.7% | -115.94% | -69.9% | -62.38% | -47.32% | -44.39% |
EBITDA Growth % | - | -65.85% | -34% | -58.93% | -64.49% | 31.49% | 12.07% | 26.51% | 28.05% |
D&A (Non-Cash Add-back) | 63K | 432K | 554K | 1.2M | 1.25M | 614K | 712K | 487K | 338K |
EBIT | -14.3M | -23.9M | -32.23M | -58.41M | -81.73M | -50.03M | -46.61M | -37.1M | -36.66M |
Net Interest Income | 1K | -1.79M | -2.37M | -4.37M | -4.47M | -5.41M | -4.66M | -1.17M | -751K |
Interest Income | 1K | 174K | 30K | 0 | 0 | 0 | 0 | 3.97M | 1.86M |
Interest Expense | 0 | 1.96M | 2.4M | 4.37M | 4.47M | 5.41M | 4.66M | 5.14M | 2.61M |
Other Income/Expense | 1K | -1.82M | -2.44M | -11.29M | -2.24M | 1.84M | -739K | -1.32M | -1.62M |
Pretax Income | -14.3M▲ 0% | -25.86M▼ 80.9% | -34.63M▼ 33.9% | -62.77M▼ 81.3% | -86.19M▼ 37.3% | -55.44M▲ 35.7% | -51.27M▲ 7.5% | -38.42M▲ 25.1% | -37.27M▲ 0% |
Pretax Margin % | -189.85% | -110.76% | -125.3% | -128.22% | -120.84% | -68.39% | -64.2% | -49.66% | -46.85% |
Income Tax | -6K | 8K | 61K | 188K | 47K | 110K | 236K | 10K | -20K |
Effective Tax Rate % | 0.04% | -0.03% | -0.18% | -0.3% | -0.05% | -0.2% | -0.46% | -0.03% | 0.05% |
Net Income | -14.29M▲ 0% | -25.87M▼ 81.0% | -34.69M▼ 34.1% | -62.96M▼ 81.5% | -86.24M▼ 37.0% | -55.55M▲ 35.6% | -51.51M▲ 7.3% | -38.43M▲ 25.4% | -37.25M▲ 0% |
Net Margin % | -189.77% | -110.8% | -125.52% | -128.61% | -120.9% | -68.53% | -64.49% | -49.67% | -46.83% |
Net Income Growth % | - | -81.03% | -34.11% | -81.48% | -36.98% | 35.59% | 7.27% | 25.4% | 24.58% |
Net Income (Continuing) | -14.29M | -25.87M | -34.69M | -62.96M | -86.24M | -55.55M | -51.51M | -38.43M | -37.25M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.44▲ 0% | -0.77▼ 75.0% | -0.74▲ 3.9% | -1.33▼ 79.7% | -1.80▼ 35.3% | -1.14▲ 36.7% | -1.03▲ 9.6% | -0.74▲ 28.2% | -0.69▲ 0% |
EPS Growth % | - | -75% | 3.9% | -79.73% | -35.34% | 36.67% | 9.65% | 28.16% | 27.71% |
EPS (Basic) | -0.44 | -0.55 | -0.74 | -1.33 | -1.80 | -1.14 | -1.03 | -0.74 | - |
Diluted Shares Outstanding | 32.2M | 33.63M | 46.77M | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M | 53.94M |
Basic Shares Outstanding | 32.2M | 33.63M | 46.77M | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M | 53.94M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
SGHT Balance Sheet
Sight Sciences, Inc. (SGHT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.16M | 28M | 70.63M | 277.04M | 209.68M | 162.87M | 139.77M | 112.73M | 106.51M |
Cash & Short-Term Investments | 4.24M | 21.24M | 61.51M | 260.69M | 185M | 138.13M | 120.36M | 91.97M | 84.96M |
Cash Only | 4.24M | 21.24M | 61.51M | 260.69M | 185M | 138.13M | 120.36M | 91.97M | 84.96M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.81M | 4.09M | 5.36M | 8.71M | 15.15M | 14.29M | 10.79M | 9.74M | 10.6M |
Days Sales Outstanding | 87.98 | 64 | 70.82 | 64.93 | 77.51 | 64.34 | 49.29 | 45.98 | 45.53 |
Inventory | 486K | 2.24M | 2.6M | 3.48M | 6.11M | 7.85M | 6.33M | 7.77M | 7.01M |
Days Inventory Outstanding | 75.87 | 125.16 | 102.97 | 147.31 | 180.54 | 241.13 | 199.35 | 265.02 | 240.27 |
Other Current Assets | 0 | 0 | 0 | 0 | 3.42M | 2.6M | 2.31M | 3.26M | 3.95M |
Total Non-Current Assets | 930K | 2.74M | 2.17M | 3.15M | 3.4M | 3.78M | 3.06M | 2.57M | 3.19M |
Property, Plant & Equipment | 868K | 2.57M | 1.79M | 2.95M | 3.19M | 3.1M | 2.52M | 2.05M | 2.82M |
Fixed Asset Turnover | 8.68x | 9.08x | 15.47x | 16.60x | 22.40x | 26.16x | 31.76x | 37.77x | 34.83x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 62K | 168K | 386K | 202K | 211K | 682K | 550K | 518K | 370K |
Total Assets | 8.09M▲ 0% | 30.74M▲ 279.8% | 72.81M▲ 136.8% | 280.19M▲ 284.8% | 213.07M▼ 24.0% | 166.65M▼ 21.8% | 142.84M▼ 14.3% | 115.3M▼ 19.3% | 109.7M▲ 0% |
Asset Turnover | 0.93x | 0.76x | 0.38x | 0.17x | 0.33x | 0.49x | 0.56x | 0.67x | 0.69x |
Asset Growth % | - | 279.8% | 136.84% | 284.84% | -23.95% | -21.79% | -14.29% | -19.28% | -72.26% |
Total Current Liabilities | 2.9M | 7.34M | 9.31M | 13.5M | 17.82M | 12.25M | 15.47M | 11.03M | 18.16M |
Accounts Payable | 1.88M | 2.31M | 2.16M | 3.35M | 2.69M | 1.73M | 1.69M | 1.34M | 1.49M |
Days Payables Outstanding | 293.34 | 129.12 | 85.53 | 142.06 | 79.37 | 53.18 | 53.3 | 45.83 | 55.12 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.22M | 0 | 0 | 3.8M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 328K | 0 | 4.07M | 5.99M | 7.35M | 4.53M | 9.68M | 9.21M | 12.88M |
Current Ratio | 2.47x | 3.82x | 7.58x | 20.52x | 11.77x | 13.29x | 9.04x | 10.22x | 5.86x |
Quick Ratio | 2.31x | 3.51x | 7.30x | 20.26x | 11.43x | 12.65x | 8.63x | 9.52x | 5.48x |
Cash Conversion Cycle | -129.49 | 60.04 | 88.26 | 70.19 | 178.68 | 252.3 | 195.34 | 265.18 | 230.68 |
Total Non-Current Liabilities | 34.16M | 78.09M | 152.34M | 34.58M | 35.18M | 34.18M | 39.85M | 40.33M | 37.64M |
Long-Term Debt | 34.15M | 12.86M | 31.95M | 32.66M | 33.31M | 31.71M | 39.36M | 40.3M | 0 |
Capital Lease Obligations | 0 | 528K | 134K | 1.04M | 635K | 914K | 473K | 0 | 230K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 7K | 64.7M | 120.25M | 879K | 1.23M | 1.56M | 19K | 31K | 37.64M |
Total Liabilities | 37.06M | 85.42M | 161.66M | 48.08M | 53M | 46.44M | 55.32M | 51.36M | 55.8M |
Total Debt | 34.15M | 13.94M | 32.48M | 34.21M | 34.98M | 35.41M | 40.36M | 40.77M | 3.8M |
Net Debt | 29.91M | -7.3M | -29.03M | -226.48M | -150.02M | -102.72M | -80M | -51.19M | -81.17M |
Debt / Equity | - | - | - | 0.15x | 0.22x | 0.29x | 0.46x | 0.64x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 2.30x |
Interest Coverage | - | -12.19x | -13.41x | -13.38x | -18.30x | -9.25x | -10.00x | -7.21x | -14.04x |
Total Equity | -28.96M▲ 0% | -54.68M▼ 88.8% | -88.85M▼ 62.5% | 232.11M▲ 361.2% | 160.08M▼ 31.0% | 120.22M▼ 24.9% | 87.52M▼ 27.2% | 63.94M▼ 26.9% | 53.9M▲ 0% |
Equity Growth % | - | -88.81% | -62.48% | 361.24% | -31.03% | -24.9% | -27.19% | -26.94% | -120.92% |
Book Value per Share | -0.90 | -1.63 | -1.90 | 4.89 | 3.35 | 2.47 | 1.75 | 1.23 | 1.00 |
Total Shareholders' Equity | -28.96M | -54.68M | -88.85M | 232.11M | 160.08M | 120.22M | 87.52M | 63.94M | 53.9M |
Common Stock | 9K | 9K | 9K | 48K | 48K | 49K | 51K | 54K | 54K |
Retained Earnings | -29.48M | -55.35M | -90.04M | -153M | -239.24M | -294.79M | -346.3M | -384.72M | -397.7M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -34.15M | -64.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SGHT Cash Flow Statement
Sight Sciences, Inc. (SGHT) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -14.47M | -25M | -32.17M | -52.54M | -75.97M | -47.18M | -22.35M | -29.69M | -25.12M |
Operating CF Margin % | -192.23% | -107.06% | -116.4% | -107.32% | -106.5% | -58.21% | -27.99% | -38.38% | - |
Operating CF Growth % | - | -72.69% | -28.71% | -63.3% | -44.59% | 37.89% | 52.63% | -32.85% | -1444.27% |
Net Income | -14.29M | -25.87M | -34.69M | -62.96M | -86.24M | -55.55M | -51.51M | -38.43M | -37.25M |
Depreciation & Amortization | 63K | 295K | 554K | 632K | 710K | 614K | 712K | 487K | 690K |
Stock-Based Compensation | 52K | 118K | 497K | 5.08M | 12.96M | 14.58M | 17.08M | 13.05M | 8.81M |
Deferred Taxes | 0 | 0 | 0 | 7.76M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 58K | 800K | 684K | 1.27M | 2.3M | 2.3M | 2.37M | 1.59M | 3.69M |
Working Capital Changes | -358K | -341K | 784K | -4.33M | -5.7M | -9.13M | 9M | -6.39M | -1.05M |
Change in Receivables | -1.42M | -2.32M | -1.48M | -3.69M | -6.84M | 661K | 3.54M | 912K | -1.14M |
Change in Inventory | -184K | -1.8M | -1.72M | -1.31M | -3.25M | -2.16M | 1.63M | -1.44M | -1.2M |
Change in Payables | 1M | 168K | 448K | 1.17M | -694K | -883K | 336K | -348K | -943K |
Cash from Investing | -570K | -672K | -953K | -813K | -970K | -791K | -385K | -224K | -284K |
Capital Expenditures | -570K | -672K | -953K | -813K | -970K | -791K | -385K | -224K | -284K |
CapEx % of Revenue | 7.57% | 2.88% | 3.45% | 1.66% | 1.36% | 0.98% | 0.48% | 0.29% | 0.36% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 12.2M | 42.66M | 73.4M | 252.53M | 1.25M | 1.1M | 4.96M | 1.79M | 1.86M |
Debt Issued (Net) | 0 | 14M | 20.48M | 0 | 0 | 0 | 4.15M | 0 | 0 |
Equity Issued (Net) | 12.23M | 30.75M | 53.08M | 256.68M | 1.25M | 1.33M | 1.07M | 1.85M | 1.86M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1K |
Other Financing | -23K | -2.09M | -154K | -4.15M | 0 | -224K | -261K | -58K | 5K |
Net Change in Cash | -2.84M▲ 0% | 17M▲ 698.0% | 40.27M▲ 137.0% | 199.18M▲ 394.6% | -75.69M▼ 138.0% | -46.87M▲ 38.1% | -17.77M▲ 62.1% | -28.13M▼ 58.3% | -23.54M▲ 0% |
Free Cash Flow | -15.04M▲ 0% | -25.67M▼ 70.6% | -33.13M▼ 29.1% | -53.35M▼ 61.1% | -76.94M▼ 44.2% | -47.98M▲ 37.6% | -22.74M▲ 52.6% | -29.92M▼ 31.6% | -25.4M▲ 0% |
FCF Margin % | -199.8% | -109.94% | -119.85% | -108.98% | -107.86% | -59.19% | -28.47% | -38.67% | -31.93% |
FCF Growth % | - | -70.61% | -29.05% | -61.06% | -44.2% | 37.64% | 52.61% | -31.59% | -3.94% |
FCF per Share | -0.47 | -0.76 | -0.71 | -1.12 | -1.61 | -0.99 | -0.45 | -0.57 | -0.47 |
FCF Conversion (FCF/Net Income) | 1.01x | 0.97x | 0.93x | 0.83x | 0.88x | 0.85x | 0.43x | 0.77x | 0.68x |
Interest Paid | 0 | 1.15M | 1.29M | 0 | 0 | 0 | 0 | 0 | 1.06M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SGHT Key Ratios
Sight Sciences, Inc. (SGHT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -87.9% | -43.98% | -39.64% | -49.59% | -50.74% | -59.1% |
Return on Invested Capital (ROIC) | - | - | -686.25% | -802.98% | -311.76% | -302.85% | -274.4% | -1490.97% |
Gross Margin | 71.97% | 66.68% | 82.41% | 82.67% | 85.34% | 85.5% | 86.17% | 86.17% |
Net Margin | -110.8% | -125.52% | -128.61% | -120.9% | -68.53% | -64.49% | -49.67% | -46.83% |
Debt / Equity | - | - | 0.15x | 0.22x | 0.29x | 0.46x | 0.64x | 0.07x |
Interest Coverage | -12.19x | -13.41x | -13.38x | -18.30x | -9.25x | -10.00x | -7.21x | -14.04x |
FCF Conversion | 0.97x | 0.93x | 0.83x | 0.88x | 0.85x | 0.43x | 0.77x | 0.68x |
Revenue Growth | 210.07% | 18.38% | 77.12% | 45.7% | 13.63% | -1.47% | -3.13% | 1.85% |
Related:SGHT Dividend History·SGHT Revenue History·SGHT Price History·SGHT P/E History·SGHT Financial Ratios·SGHT Institutional Holders
SGHT SEC Filings & Documents
Sight Sciences, Inc. (SGHT) SEC filings — annual & quarterly reports (10-K, 10-Q)
SGHT Frequently Asked Questions
Sight Sciences, Inc. (SGHT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sight Sciences, Inc. (SGHT) reported $79.6M in revenue for fiscal year 2025. This represents a 956% increase from $7.5M in 2018.
Sight Sciences, Inc. (SGHT) saw revenue decline by 3.1% over the past year.
Sight Sciences, Inc. (SGHT) reported a net loss of $37.3M for fiscal year 2025.
Dividend & Returns
Sight Sciences, Inc. (SGHT) has a return on equity (ROE) of -50.7%. Negative ROE indicates the company is unprofitable.
Sight Sciences, Inc. (SGHT) had negative free cash flow of $25.4M in fiscal year 2025, likely due to heavy capital investments.